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Self assembling peptide 
A B S T R A C T   
Background: Pelvic surgery has the potential to leave behind a large raw surface, which can bleed and ooze 
postoperatively. The adoption of precision surgical approach for rectal cancers has led to reduction in blood loss. 
We aimed to assess 1) the feasibility and 2) the safety of using a self-assembling peptide (SAP) haemostatic agent 
(PuraStat®) after rectal cancer surgery to reduce the incidence of pelvic collections. 
Materials and methods: This prospective cohort pilot study compared the results of 25 consecutive cases of total 
mesorectal excision (TME) with use of 5–10 ml of SAP, and 25 consecutive cases without PuraStat® application 
(CON, control group). The groups were compared for complications (Clavien-Dindo grade III and IV classifica-
tion), postoperative drain output and length of hospital stay (LOS). Statistical analysis was carried out using 
paired samples T test and Fisher’s exact test 
Results: Fifty patients (SAP = 25, CON = 25) were enrolled into this study. Mean drain outputs (ml) on day 1, day 
2 and day 3 were 60 ± 18, 89 ± 42 and 64 ± 45 in SAP group, and 102 ± 31, 95 ± 52, 66 ± 37 in CON group. 
This was significantly better for SAP group in day one after surgery. The mean LOS was shorter in SAP group (5.7 
versus 7.4 days in CON, p 0.04). Clavien-Dindo III & IV complications were seen in two and five cases respec-
tively (p 0.18). R0 resection rate (p 0.32) and lymph node harvest (p 0.13) were similar in both groups. There 
were no complications seen in relation to the application of the SAP. 
Conclusions: These initial data suggest that SAP is a safe product, and feasible to apply in the pelvis after TME 
surgery. It appears to shorten the LOS and reduce the postoperative drain output and may reduce the incidence of 
Clavien-Dindo grade III & IV complications.   
1. Introduction 
Pelvic surgery has the potential to leave behind a large raw surface, 
which can cause small amounts of capillary bleeding and oozing after 
surgery. These fluids are either absorbed by the peritoneum or can 
develop into a postoperative collection. Significant output from post-
operative pelvic drains requires the drains to stay for a period of 24–72 h 
[1–3]. Keeping a surgical drain longer than 48 h could lead to a delay in 
discharging the patient from hospital and poor compliance with the 
enhanced recovery program (ERP) in colorectal surgery [4]. Further-
more, any infection in the area may convert this collection into an ab-
scess, which may compromise anastomotic healing [5]. The adoption of 
precision surgical approach for rectal cancers has led to minimal blood 
loss intraoperatively; however pelvic drains are still needed after TME to 
avoid pelvic collection. 
There are conflicting results in various studies [6,7] on whether to 
drain the pelvis or not. The situation is complex due to the heterogeneity 
of these studies and lack of adequate information with respect to level of 
lesion, level of anastomosis (extraperitoneal or intraperitoneal), type of 
drain used, use of preoperative therapy, indication for surgery (emer-
gency or elective), intraoperative bleeding, and other risk factors [1–3]. 
Minor capillary oozing and lymphatic leakage may go unnoticed 
during surgery especially concealed by the pressure effect of the pneu-
moperitoneum, leading to the development of a pelvic hematoma or 
* Corresponding author. Queen Alexandra Hospital, NHS Portsmouth Southwick Hill Road, Portsmouth, PO6 3LY, UK. 
E-mail addresses: samvimars@gmail.com (S. Stefan), Jim.Khan@porthosp.nhs.uk (J. Khan).  
Contents lists available at ScienceDirect 
Annals of Medicine and Surgery 
journal homepage: www.elsevier.com/locate/amsu 
https://doi.org/10.1016/j.amsu.2021.102553 
Received 30 April 2021; Received in revised form 7 July 2021; Accepted 7 July 2021   
Annals of Medicine and Surgery 68 (2021) 102553
2
collection afterwards [2]. Therefore, there is a further need to use a 
preventative treatment and to assess its efficiency and safety. 
Most conventional topical haemostatic agents obscure visibility once 
applied, making further surgical assessment of the area difficult. Pura-
Stat® (3-D Matrix Europe SAS, France) is an inert, synthetic, transparent 
haemostatic hydrogel comprised of self-assembling peptides (SAPs), 
which spreads easily over uneven surfaces and hard to reach areas [8]. 
Previous studies in resectional endoscopy [8–10], ENT - ear, nose and 
throat surgery [11] and cardiothoracic surgery [12–15] have revealed a 
significant reduction in the post-procedural complications with use of 
this product which reduces the oozing from capillaries and prevents 
secondary haemorrhage. The potential usage of a transparent SAP in 
colorectal resections has not been studied and presented so far. 
We hypothesised that a prophylactic application of a SAP on the 
pelvic raw area may prevent fluid oozing and bleeding. This study in-
tends to explore the safety and feasibility of application of SAP, with the 
aim to reduce the postoperative complications, LOS and drainage 
following surgery for rectal cancer. 
2. Materials and methods 
Patients with rectal cancer requiring TME surgery were enrolled into 
a prospective pilot cohort study. The cohort was divided into two groups 
comparing the group SAP with 25 consecutive patients receiving 
application of PuraStat® at the end of the procedure to the pelvic raw 
area, and a control (CON) group of 25 patients without Purastat® 
application. The patients were recruited over a period of four months 
(06–09/2019) and included in the study if they had a diagnosis of rectal 
cancer, were non-vulnerable adults, and willing and able to provide fully 
informed written consent for participation in the study and for the 
application of the SAP. Patients requiring multi-visceral resections, 
palliative resection, or having metastatic disease at presentation were 
excluded from the study. The project was registered with researchregistr 
y.com with the number researchregistry6505 [16]. 
All patients underwent robotic rectal resection with TME surgery, 
with a standardised technique following the colorectal multidisciplinary 
team decision (MDT). They were managed post-operatively in an ERP 
setting. All patients had mechanical bowel preparation preoperatively 
and antibiotics at induction. A 20 Fr. drain was placed routinely in the 
pelvis. Drains were removed during the third postoperative day. 
These two groups were compared for postoperative drain output and 
recovery parameters, complications (morbidity and mortality), and LOS. 
The postoperative complications were graded using the Clavien-Dindo 
classification [17]. Prolonged ileus was defined as lack of bowel or 
stoma function for more than three days after surgery. Anastomotic leak 
was defined as radiological or clinically palpable defect in the anasto-
mosis. A pelvic collection or abscess was diagnosed on a computed to-
mography (CT) scan. CT scans were carried out for the patients who had 
prolonged ileus (>72 h), raised inflammatory markers (CRP>250) or 
clinical features of sepsis. 
2.1. SAP application 
The nursing team were trained on the preparation of the product. An 
endoscopic applicator (E-Type nozzle system, Top Corporation, Japan) 
was used to allow the surgeon at the console to manage the application 
of PuraStat® with the robotic instruments in a controlled fashion 
(Fig. 1). A paintbrush technique was used to apply a thin layer of SAP 
over the pelvic raw area at the end of the procedure; the volume 
required was between 5 and 10 mL, and the injection was made by the 
bedside assistant but controlled by the operating surgeon using the ro-
botic instruments. 
The product is ready-to-use in a prefilled syringe and it is deployed as 
a physical barrier to mitigate oozing. It is applied ergonomically in the 
pelvis and spread in a thin layer to cover the pelvic raw surface (Fig. 2). 
Three learning curve cases were undertaken to develop this appli-
cation technique, to understand the volume of SAP required and thus to 
standardise the application method. These three patients were con-
sented for the study but not included in the analysis of this pilot study, as 
per consort flow chart (Fig. 3). 
This cohort study presents original research and is compliant with 
the STROCSS criteria checklist (Strengthening the reporting of cohort 
studies in surgery) [18]. 
2.2 Data analysis 
Statistical analysis used IBM SPSS® Statistics for Windows, Version 
24 (IBM, Chicago, IL). The distribution of data was assessed using 
descriptive methods (skewness, outliers, and distribution plots) and 
inferential statistics (Shapiro-Wilk test).Where there was no normal 
distribution, non-parametric analyses were performed. Data are pre-
sented as mean (SD). Paired samples T test was used for numerical data, 
with p value of <0.05 as significant, and Fisher’s exact test was used to 
compare categorical data if the total sample size was small. 
3. Results 
A total of 50 patients completed the study. Patient demographics 
Fig. 1. Preparation (right side photograph) and injection (left) of the haemostatic gel.  
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were similar between the two groups with regards to age, gender and 
BMI (Table 1). Mean age was 65 ± 11 years and 67 ± 13 years in SAP 
and CON groups respectively, with a mean BMI of 26.6 ± 5 and 26 ± 4. 
Neo-adjuvant radiotherapy for downstaging was given to three pa-
tients in SAP, and to four in CON group. Both groups were comparable 
for tumour stage and nodal involvement. 
The recovery parameters included measurements of the drain output 
and the length of hospital stay. Mean drain outputs on day 1, day 2 and 
day 3 were 60 ± 18 ml, 89 ± 42 ml and 64 ± 45 ml in SAP group, and 
102 ± 31 ml, 95 ± 52 ml, 66 ± 37 ml in CON group (Fig. 4), with a 
significant difference in day 1. 
The surgical approach was a single docking standardised robotic 
TME surgery using daVinci® platform. IMA and IMV were divided and 
splenic flexure fully mobilised followed by TME in the pelvis down to the 
pelvic floor. Specimen was extracted via a Pfannenstiel incision and an 
end-to-end stapled colorectal anastomosis was fashioned [19]. 
The majority of cancers were locally advanced (T3 and T4) and 
required a low or ultra-low resection with a high-risk bowel anasto-
mosis, hence a temporary stoma was considered (Table 2). 
The mean time needed for the application of the SAP was 5 min 
(range 4–10 min). The mean operating time for SAP was 261 ± 39 min 
and 270 ± 79 min for CON (p 0.57). Both groups had a mean intra-
operative blood loss of 20 ml (range 10–50 ml). There were no con-
versions to open surgery in both groups. 
The mean LOS was 5.68 days for patients in SAP group and 7.44 days 
in CON group; this difference was statistically significant, p = 0.04 
(Table 2). There was no mortality within 90 days after surgery. 
The oncological outcomes were not different between SAP and CON 
Fig. 2. Application of PuraStat® in the pelvis - intraperitoneal view.  
Fig. 3. Consort flow chart of the study.  
Table 1 
Patient characteristics.   
SAP (n = 25) CON (n = 25) P value 
Mean age (range)a 65 ± 11 (32–88) 67 ± 13 (33–84) 0.48 
Male/female 60/40 56/44 0.25 
Mean BMI (range) 26.6 ± 5 (19–37) 26 ± 4 (19–37) 0.73 
ASA I & II 16 (64%) 23 (92%) 0.49 
ASA III & IV 9 (36%) 2 (8%)  
Tumour stage: 
T1 & T2 













a Data are presented as mean ± standard deviation, or as a percentage. N.B. 
BMI: Body Mass Index, ASA: American Society of Anesthesiologists. 
Fig. 4. Comparison of the drain output during the first three days after surgery.  
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for R0 resection (p 0.32) and lymph node count (p 0.13). 
Postoperative grade III/IV Clavien-Dindo complications [17] were 
seen in two cases in SAP group and in five cases in CON group (Tables 2 
and 3). The pelvic abscesses were diagnosed on postoperative CT scan 
performed if clinically indicated. 
4. Discussion 
To date, this is the first study to assess the use of a fluid haemostatic 
product in colorectal surgery. Specifically, this original research 
compared the use of a SAP with a control group undergoing rectal cancer 
operations. We hypothesised a no difference between the surgical out-
comes in these groups and we found a series of statistically significant 
differences related to the surgical drain output and the LOS. 
Precision oncological surgery is becoming the new paradigm in 
cancer management. In the era of minimally invasive surgery the peri-
operative blood loss is minimal. Newer tools allow surgeons to dissect 
better, without bleeding, and to avoid complications. The pelvic raw 
area after rectal cancer surgery can be a source of continuous oozing and 
lympho-vascular fluid can accumulate in the pelvis as postoperative 
hematoma/fluid collections. These could subsequently become infected, 
with formation of abscesses and leaks. For this very reason the routine 
use of pelvic drains after rectal cancer surgery has not been completely 
abolished [4]. 
The drain volume after rectal cancer surgery is dependent on various 
factors including surgical technique, factors related to the patients 
(obesity, narrow pelvis, and use of anticoagulants), and factors related to 
the cancer - such as tumour stage, size, and preoperative radiotherapy, 
and development of postoperative complications [4]. The mean drain 
volume in this study was significantly lower in the first postoperative 
day for the patients treated with SAP. Similarly, the length of hospital 
stay was shorter which probably reflects successful adherence to the 
ERP. 
PuraStat® is a biocompatible, synthetic, self-assembling peptide 
haemostatic hydrogel; it is an inert, sterile solution, hence the risk of 
postoperative infection caused by the gel should be minimal. Our data 
did not suggest any increased risk of abscess formation or sepsis in the 
group treated with SAP application. 
These SAPs form a three-dimensional nanofibre matrix when 
exposed to ionic fluids [8]. PuraStat is approved and CE marked for 
haemostasis during surgery in oozing bleeding in parenchyma of solid 
organs, vascular anastomoses and small vessels and capillaries in the 
gastrointestinal tract; it is additionally indicated for reduction of 
delayed bleeding following colonic ESD - endoscopic submucosal 
dissection [8–10]. We have considered the use of SAP only for the 
haemostatic purpose, and not for other reasons. As mentioned in the 
methodology, the aim of this study was to assess the ability of the gel to 
reduce the postoperative bleeding/oozing leading to the development of 
pelvic collection. 
In 2006 Ellis-Behnke RG et al. published for the first time an animal 
experiment and demonstrated the use of a synthetic, non-toxic and non- 
immunogenic self-assembling peptide that forms a nanofibre barrier to 
establish immediate haemostasis when applied to open wounds [20]. 
PuraStat® has also been used in nasal endoscopic procedures, endo-
scopic resections in the GI tract and cardiac surgeries with promising 
results [8–11]. Apart from preventing primary oozing and leakage, the 
use of haemostatic agents has been described to prevent a secondary 
haemorrhage. Most of the studies in this context originate from vascular 
surgery where the risk of postoperative bleeding is high [12–15]. 
Masuhara et al. further established the efficacy of this agent in 
achieving intra-operative haemostasis in humans when applied to 
vessel-to-vessel anastomotic site. They reported no adverse effect and no 
post-operative bleed and suggested that this agent might be safer over 
other human or animal derived topical haemostatic agents who carry an 
inherent risk of transmitting infection and causing hypersensitivity re-
actions [14]. In another prospective non-randomised study of PuraStat® 
in cardiac surgery, Giritharan et al. showed similar results in terms of 
safety and efficacy of this agent [12]. They reported that the 
post-operative use of blood products in their series was below that of 
national average. Analysis of questionnaire given to ten operating sur-
geons scored this agent high in various subcategories including ease of 
application, time to coagulation, cross compatibility with other hae-
mostatic agents and transparent nature of PuraStat® which does not 
obscure vision, thereby allowing further assessment of the operative 
field [13]. The drawbacks of this study are the lack of randomisation, 
and absence of patient stratification. The ongoing SASH trial (Strategy 
for aortic surgery haemostasis), which is in it a recruitment phase, is 
expected to provide a better level of evidence with regards to the hae-
mostatic potential of this agent, in view of its randomised nature and 
focused patient selection [15]. 
In 2017, Lee et al. reported the efficacy of PuraStat® in achieving 
haemostasis in 60 patients undergoing endo-nasal powered turbino-
plasty [11]. Subramaniam et al. in their study of 100 patients under-
going ESD and endoscopic mucosal resections at various sites reported a 
good haemostatic efficacy, even in patients on anticoagulation with an 
acceptable delayed bleeding rate of 3%. They also pointed out towards 
rapid onset of action of PuraStat® and reduction in use of electrocautery 
to achieve haemostasis [9,10]. The most recently publication from this 
group compares the use of this SAP to cautery for oozing bleeding, in a 
pragmatically designed RCT of high risk oesophageal and colonic ESD, 
with 101 patients undergoing ESD in a single centre. They report a 
haemostatic efficacy of 92.6%, with a delayed bleed rate of 4.3% [9]. 
De Nucci et al. (2020) have recently published data of their 3-centre 
observational study, using PuraStat® in acute gastrointestinal bleeds, on 
a cohort of 77 patients, over 2 years. They report a 90.3% haemostatic 
efficacy, with failure in 7/13 spurting bleeds. The re-bleed rate reported 
is 10.3% which compares well with the literature in this cohort [21]. 
Kondo et al. published their results of the use of a similar first generation 
self-assembling synthetic peptide named PuraMatrix® in achieving 
haemostasis following surgery for rectal cancer. They reported signifi-
cant reduction in postoperative drainage in 10 patients, compared to 10 
controls [22]. Our pilot study for application of SAP in colorectal cancer 
surgery revealed a significant reduction in drain output for the first 
postoperative day (Fig. 4). 
The study also assessed the feasibility of application of SAP in the 
pelvis after robotic TME surgery. We evaluated the ease of application 
and standardised the technique while assessing any effects or compli-
cations from its use. Although there were more patients with read-
mission in SAP group, they only needed management for Clavien-Dindo 
grade I/II complications (Tables 2 and 3). The pelvic collections in SAP 
Table 2 
Postoperative outcomes.   
Group 1 (n = 25) Group 2 (n = 25) P value 
Mean operating time (min)a 261 ± 39 270 ± 79 0.57 
Conversion to laparotomy 0 0  
Temporary stoma rate 13 (52%) 14 (56%) 0.78 
Length of stay (days) 5.68 7.44 0.04 
Clavien-Dindo grade III/IV 2 (8%) 5 (20%) 0.18 
Compliance with ERP 20 (80%) 19 (76%) 0.23 
R0 resection rate 24 (96%) 24 (96) 0.32 
Lymph node harvest 33 26 0.13  
a Data are presented as mean (SD), numbers, or as a percentage. 
Table 3 
Postoperative morbidity.   
SAP (n = 25) CON (n = 25) P value 
Postoperative ileus 2 5 0.18 
Pelvic abscess/collection 3 5 0.42 
Anastomotic leak 1 1 n/a 
Readmission 6 4 0.49 
Reoperation 0 2 0.16  
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group were managed conservatively, whilst two patients in CON group 
had interventional radiology drainage. Most of the postoperative com-
plications in the CON group occurred during the index admission. Two 
re-admissions led to re-operation due to postoperative abscess: abdom-
inal washout and defunctioning ileostomy in one case, and a Hartmann’s 
procedure for anastomotic leak in the second case were carried out 
(Table 3). 
The limitations of this original research study include a small sample 
size and lack of randomisation. RCT design to assess further the effects of 
this intervention is required. It might be difficult to blind the operating 
team with a placebo product; however blind assessors of the outcome 
measures could be used. The outcomes of a potential RCT shall point 
towards routine use of a SAP as standard of care, and further a tailored 
application of SAP to any particular surgical case. 
Another limitation of this pilot study is represented by inclusion of 
patients who had preoperative radiotherapy to the pelvis for down-
staging purpose. Although a limited number of patients had neoadjuvant 
radiotherapy (3, respectively 4), this is a known risk factor for increased 
drainage output due to the presence of irradiated scarred tissue [4]. 
A recent review has also mentioned other potential uses of SAP in 
surgery, namely surgical haemostasis, haemostasis for radiation- 
induced proctitis, promotion of wound healing and tissue regenera-
tion, and reduction of postoperative adhesions [23]. Future extended 
studies should take into consideration some of these new parameters as 
potential beneficial outcomes for the patients undergoing TME for 
cancer. 
5. Conclusions 
Use of SAP is safe and is associated with significantly reduced drain 
output after rectal cancer surgery and reduction in length of stay, and 
possible reduction in post operative complications. Further studies are 
necessary to establish the efficacy of prophylactic application of SAP 
after TME surgery. 
Ethical Approval 
Granted - The study involves use of an inert, non-biological, product 
that has already been used in practice in other medical specialties: 
Gastroenterology, Endoscopy, ENT, Cardio-vascular Surgery, and with 
no reports of adverse reactions.The study has been registered with the 
local Audit Department with the registration number 4949, and has been 
brought to the local Research & Development Department. 
Funding 
This work was supported by 3-D Matrix Europe SAS that provided the 
PuraStat® product and the applicator needed for this pilot study. The 
company representative has also provided support by reviewing the 
manuscript on one occasion. 
Author contribution 
Please specify the contribution of each author to the paper, e.g. study 
design, data collections, data analysis, writing. Others, who have 
contributed in other ways should be listed as contributors. Jim Khan – 
conceptualization, methodology, writing – review & editing, supervi-
sion, Samuel Stefan – data curation, formal analysis, writing original 
draft, Najaf Siddiqi – supervision, Syed Naqvi – manuscript review, 
Emma Rawlinson – data curation, Mira Wagh – writing - literature re-
view, references, Anthony Shepherd – writing – review & editing, 
validation. 
Guarantor 
The Guarantor is the one or more people who accept full 
responsibility for the work and/or the conduct of the study, had access to 
the data, and controlled the decision to publish. Please note that 
providing a guarantor is compulsory. 
Declaration of competing interest 
None. 
Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.amsu.2021.102553. 
References 
[1] H.Y. Zhang, C.L. Zhao, J. Xie, Y.W. Ye, J.F. Sun, Z.H. Ding, et al., To drain or not to 
drain in colorectal anastomosis: a meta-analysis 31 (5) (2016 May) 951–960, 
https://doi.org/10.1007/s00384-016-2509-6. 
[2] Q. Denost, P. Rouanet, J.L. Faucheron, Y. Panis, B. Meunier, E. Cotte, et al., To 
drain or not to drain infraperitoneal anastomosis after rectal excision for cancer: 
the GRECCAR 5 randomized trial. French research group of rectal cancer surgery 
(GRECCAR), Ann. Surg. 265 (3) (2017) 474–480. 
[3] F. Rondelli, W. Bugiantella, M.C. Vedovati, R. Balzarotti, N. Avenia, E. Mariani, et 
al., To drain or not to drain extraperitoneal colorectal anastomosis? A systematic 
review and meta-analysis, Colorectal Dis. 16 (2) (2014 Feb) O35–O42. 
[4] P.M. King, J.M. Blazeby, P. Ewings, P.J. Franks, R.J. Longman, A.H. Kendrick, et 
al., Randomized clinical trial comparing laparoscopic and open surgery for 
colorectal cancer within an enhanced recovery programme, Br. J. Surg. 93 (3) 
(2006 Mar) 300–308, https://doi.org/10.1002/bjs.5216. 
[5] W.M. Chambers, N.J.M. Mortensen, Postoperative leakage and abscess formation 
after colorectal surgery, Best Pract. Res. Clin. Gastroenterol. 18 (5) (2004 Oct) 
865–880, https://doi.org/10.1016/j.bpg.2004.06.026. 
[6] F. Guerra, G. Giuliani, D. Coletta, M. Boni, F. Rondelli, P.P. Bianchi, et al., A meta- 
analysis of randomised controlled trials on the use of suction drains following 
rectal surgery, Dig. Surg. 35 (2018) 482–490. 
[7] D. Cavaliere, G. Popivanov, D. Cassini, R. Cirocchi, B.M. Henry, N. Vettoretto, et 
al., Is a drain necessary after anterior resection of the rectum? A systematic review 
and meta-analysis, Int. J. Colorectal Dis. 34 (6) (2019 Jun) 973–981. 
[8] M. Pioche, M. Camus, J. Rivory, S. Leblanc, I. Lienhart, M. Barret, et al., A self- 
assembling matrix-forming gel can be easily and safely applied to prevent delayed 
bleeding after endoscopic resections, Endosc. Int. Open 4 (4) (2016) E415–E419, 
https://doi.org/10.1055/s-0042-102879. 
[9] S. Subramaniam, K. Kandiah, F. Chedgy, C. Fogg, S. Thayalasekaran, A. Alkandari, 
et al., A novel self-assembling peptide for hemostasis during endoscopic 
submucosal dissection: a randomized controlled trial, Endoscopy 53 (1) (2021 Jan) 
27–35, https://doi.org/10.1055/a-1198-0558. Epub 2020 Jul 17. 
[10] S. Subramaniam, K. Kandiah, S. Thayalasekaran, G. Longcroft-Wheaton, 
P. Bhandari, Haemostasis and prevention of bleeding related to ER: the role of a 
novel self-assembling peptide, United European Gastroenterol J 7 (1) (2019) 
155–162, https://doi.org/10.1177/2050640618811504. 
[11] M.F. Lee, Z. Ma, A. Ananda, A novel haemostatic agent based on self-assembling 
peptides in the setting of nasal endoscopic surgery, a case series, Int J Surg Case 
Rep 41 (2017) 461–464, https://doi.org/10.1016/j.ijscr.2017.11.024. 
[12] S. Giritharan, K. Salhiyyah, G.M. Tsang, S.K. Ohri, Feasibility of a novel, synthetic, 
self-assembling peptide for suture-line haemostasis in cardiac surgery, 
J. Cardiothorac. Surg. 13 (1) (2018) 68, https://doi.org/10.1186/s13019-018- 
0745-2. 
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